Coxsackievirus-induced myocarditis: new trends in treatment (Q36233532)

12 August 2017

1 reference

title

Coxsackievirus-induced myocarditis: new trends in treatment (English)

1 reference

12 August 2017

0 references

1 reference

Zhen Liu

1

1 reference

12 August 2017

Ji Yuan

2

1 reference

12 August 2017

Bobby Yanagawa

3

1 reference

12 August 2017

Dexin Qiu

4

1 reference

12 August 2017

Bruce M McManus

5

1 reference

12 August 2017

Decheng Yang

6

1 reference

12 August 2017

1 August 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

4

1 reference

12 August 2017

641-650

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

12 August 2017

1 reference

The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Hepatitis C virus infection and cardiomyopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Fulminant coxsackieviral myocarditis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Severe neonatal enteroviral hepatitis treated with pleconaril

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Treatment of potentially life-threatening enterovirus infections with pleconaril

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Structural analysis of a series of antiviral agents complexed with human rhinovirus 14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Design, synthesis, and structure-activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Progress in antisense technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Design of antisense oligonucleotides stabilized by locked nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Nucleic-acid therapeutics: basic principles and recent applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5' untranslated region of coxsackievirus B3: potential targets for antiviral action of antisense oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Structural and functional analysis of the 5' untranslated region of coxsackievirus B3 RNA: In vivo translational and infectivity studies of full-length mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

RNA silencing in plants--defense and counterdefense

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

RNA interference is mediated by 21- and 22-nucleotide RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Gene silencing in mammals by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Short interfering RNA confers intracellular antiviral immunity in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Enhanced gene silencing by the application of multiple specific small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Inhibition of respiratory viruses by nasally administered siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Overview of FTY720 clinical pharmacokinetics and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Use of intravenous gamma globulins in neuroimmunologic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Successful treatment of enterovirus-induced myocarditis with interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

An antiviral mechanism of nitric oxide: inhibition of a viral protease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Peroxynitrite inhibition of Coxsackievirus infection by prevention of viral RNA entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Cellular cardiomyoplasty: clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Microarray-based detection and genotyping of viral pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

DNA microarrays for virus detection in cases of central nervous system infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Virus diagnostics on microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

Gamma-globulin treatment of acute myocarditis in the pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.641

21 January 2018

Identifiers

DOI

10.1586/14787210.3.4.641

1 reference

12 August 2017

1 reference